Hanmi Pharm (128940.KS) Earnings Analysis

Hanmi Pharm (128940.KS) has no confirmed upcoming earnings date. It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E 25.92.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 128940.KS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 128940.KS. This page updates as the calendar is published.

128940.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-303,587.5 KRWn/an/an/a
2026-02-055,200.32 KRWn/an/an/a
2025-07-252,882.58 KRWn/an/an/a
2025-04-283,360 KRW4,276.45 KRW-21.4%Miss
2025-01-31-390.73289 KRW2,006.32 KRW-119.5%Miss
2024-10-312,445 KRW3,039.76 KRW-19.6%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

128940.KS valuation and analyst view

Trailing P/E25.92
Trailing EPS11,986.58 KRW
Price / book4.30
Dividend yield0.58%
Market cap4679.00B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Hanmi Pharm (128940.KS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 128940.KS. This page updates as the calendar is published.

Did 128940.KS beat earnings last quarter?

Consensus estimate data was not available for 128940.KS's 2026-04-30 report.

What is 128940.KS's earnings track record?

Over the last 3 reported quarters with consensus data, 128940.KS beat estimates 0 times (0%).

What is 128940.KS's current P/E ratio and EPS?

128940.KS trades at a trailing P/E of 25.92 on trailing EPS of 11986.582371750314 KRW.

What do analysts rate 128940.KS?

128940.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.